<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03794206</url>
  </required_header>
  <id_info>
    <org_study_id>CD1009</org_study_id>
    <nct_id>NCT03794206</nct_id>
  </id_info>
  <brief_title>Vesair Balloon Confirmatory Trial (VECTOR)</brief_title>
  <acronym>VECTOR</acronym>
  <official_title>CD 1009 Rev A Page 1 of 44 23OCT2018 Vesair Balloon Confirmatory Trial (VECTOR) Use of the Next Generation Vesair® Bladder Control System for the Treatment of Stress Urinary Incontinence in Post-Menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solace Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Solace Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, prospective, single-arm study to assess the safety and efficacy of the Vesair
      Bladder Control treatment in post-menopausal women with Stress Urinary Incontinence (SUI)
      with follow-up at 1, 3 and 12 months. All subjects will be prospectively treated after the
      subject has provided informed consent and determination that all study entry criteria have
      been met.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 11, 2019</start_date>
  <completion_date type="Anticipated">June 28, 2022</completion_date>
  <primary_completion_date type="Actual">August 26, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Provocative Pad Weight</measure>
    <time_frame>3 months</time_frame>
    <description>in-office Pad weight test</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-arm of subjects who receive treatment with Vesair Balloon</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vesair Balloon</intervention_name>
    <description>Treatment with Vesair Balloon for one year</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously treated with Vesair Balloon within the past 4 years

          -  Normal voiding function

          -  Has signed consent

          -  Willing to undergo cystoscopy

          -  Available for minimum of 12 months

        Exclusion Criteria:

          -  Last Menstrual Period within past 4 years

          -  Systemic birth control medication (including implants) or systemic hormone replacement
             therapy (estrogen or progesterone) in the past 4 years.

          -  History of urosepsis, bladder infection, urinary tract infection or asymptomatic
             bacteriuria within the past 3 months.

          -  Urinary incontinence of neurogenic etiology.

          -  Prior pelvic surgery that may affect incontinence symptoms (including placement and/or
             removal of a suburethral sling) within the past 4 years.

          -  Noninvasive treatment for incontinence, such as nerve stimulation, Botox injections,
             biofeedback, formal pelvic floor muscle training, and/or vaginal laser therapy, within
             the past 3 months.

          -  Taken medications other than anticholinergics that may affect SUI symptoms (such as
             enobosarm, duloxetine or imipramine) in the past 3 months.

          -  Taking other pharmacologic agents that may have a significant effect on bladder
             function unless on the therapy for at least 3 months and intending to continue the
             same dosage of the medication throughout the trial.

          -  History of recurrent (&gt;1) kidney stones, or one kidney stone within the past 5 years.

          -  History of an artificial urinary sphincter.

          -  Presence of gross hematuria and/or blood clots in the urine.

          -  History of interstitial or follicular cystitis or other painful bladder syndrome.

          -  Cystocele verified as Stage 3 or higher by PoP-Q Classification.

          -  Local genital skin infection.

          -  Urethral or bladder inflammation and/or edema, or other hypersensitivity to cystoscopy
             or other urethral manipulations.

          -  Evidence of involuntary detrusor contractions and/or discomfort during bladder filling
             up to 300cc.

          -  Undergoing or anticipating a course of pelvic radiation therapy or with severe pelvic
             fibrosis from previous radiation therapy.

          -  Non-ambulatory, bedridden or physically unable to complete test exercises.

          -  History of recent alcoholism or illicit drug abuse within the last year.

          -  Immunologically suppressed or immunocompromised.

          -  History of any neurological disease that could impact bladder function including
             Parkinson's disease, multiple sclerosis or post-stroke sequelae.

          -  Uncontrolled diabetes (persistent A1C levels &gt;9 percent).

          -  History of any malignancy (except non-melanoma skin cancer), unless the cancer was not
             in the urinary tract, the cancer was stage II or less, the cancer was treated with
             curative intent, AND there have been no clinical signs or symptoms of the malignancy
             for at least 2 years.

          -  Morbid obesity, defined as BMI ≥40.0.

          -  History of any autoimmune or connective tissue disease or disorder that could impact
             bladder function
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Rardin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women and Infants Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WomanCare</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology</name>
      <address>
        <city>Hanover</city>
        <state>Maryland</state>
        <zip>21076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology</name>
      <address>
        <city>Owings Mills</city>
        <state>Maryland</state>
        <zip>21117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants dept of Urogynecology</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Urology</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.solacetx.com</url>
    <description>Company Website</description>
  </link>
  <reference>
    <citation>McCammon K, Jacoby K, Kalota S, Snyder J, Cline K, Robertson K, Rardin C, Kahan R, Green L, Zuckerman J, Rovner E. Three-month primary efficacy data for the SUCCESS Trial; a phase III, multi-center, prospective, randomized, controlled study treating female stress urinary incontinence with the vesair intravesical balloon. Neurourol Urodyn. 2018 Jan;37(1):440-448. doi: 10.1002/nau.23324. Epub 2017 Nov 2.</citation>
    <PMID>29095516</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 3, 2019</study_first_submitted>
  <study_first_submitted_qc>January 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2019</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

